VISEN Deepens Losses as It Secures China Approval and Prepares to Launch Long-Acting Growth Hormone

VISEN Pharmaceuticals ( (HK:2561) ) has shared an update.

VISEN Pharmaceuticals reported a wider annual loss of RMB253.4 million for 2025 as research and development, administrative, and newly incurred selling and marketing expenses rose, while its cash and cash equivalents increased sharply to RMB632.6 million, bolstering its liquidity ahead of commercialization. During the year, the company advanced its core product lonapegsomatropin by securing key device approvals, strengthening supply agreements with Ascendis Pharma, progressing technology transfer and localization, and forming a strategic partnership with Tofflon on dual-chamber lyophilized technology.

Regulatory momentum continued with China’s NMPA approving the biologics license application for lonapegsomatropin, branded as SKYTROFA, for pediatric and adolescent patients aged three and above with growth hormone deficiency, with the label highlighting superior efficacy and extended room-temperature stability. VISEN has built a lean but specialized in-house commercial team and plans full-scale commercialization of lonapegsomatropin in 2026, positioning the company to transition from a development-stage biotech to a revenue-generating player in the pediatric growth hormone market.

The most recent analyst rating on (HK:2561) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on VISEN Pharmaceuticals stock, see the HK:2561 Stock Forecast page.

More about VISEN Pharmaceuticals

VISEN Pharmaceuticals is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong that focuses on pediatric endocrinology, particularly treatments for pediatric growth hormone deficiency. Its core product is lonapegsomatropin, a long-acting growth hormone therapy designed to offer superior efficacy, convenient dosing and room-temperature stability for children and adolescents with inadequate growth hormone secretion in China.

Average Trading Volume: 22,675

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$3.65B

For a thorough assessment of 2561 stock, go to TipRanks’ Stock Analysis page.